IL-6 and cystatin-C, as markers of inflammation and kidney damage, respectively, are likely to provide insight into prediction of risk for CKD outcomes after AKI, as our feasibility data suggest that IL-6 is a more sensitive than high sensitivity-CRP. This evidence concerns the gene CST3 and chronic kidney disease.